Diheteroaryl histone deacetylase inhibitors and their use in therapy
申请人:Karus Therapeutics Limited
公开号:US10407435B2
公开(公告)日:2019-09-10
The present invention is a compound having the following formula: (Formula (I)) or a pharmaceutically acceptable salt thereof, wherein e.g. X is C or N; n is 1 to 10; each L is independently a 5- to 12-membered heteroaryl containing at least two nitrogen atoms; and W is a zinc-binding group. The compounds are useful as histone deacetylase (HDAC) inhibitors.
本发明是具有下式的化合物:式(I))或其药学上可接受的盐,其中例如 X 是 C 或 N;n 是 1 至 10;每个 L 独立地是含有至少两个氮原子的 5 至 12 元杂芳基;W 是锌结合基团。这些化合物可用作组蛋白去乙酰化酶(HDAC)抑制剂。
DIHETEROARYL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY
申请人:Karus Therapeutics Limited
公开号:US20170313712A1
公开(公告)日:2017-11-02
The present invention is a compound having the following formula: (Formula (I)) or a pharmaceutically acceptable salt thereof, wherein e.g. X is C or N; n is 1 to 10; each L is independently a 5- to 12-membered heteroaryl containing at least two nitrogen atoms; and W is a zinc-binding group. The compounds are useful as histone deacetylase (HDAC) inhibitors.
Preparation and palladium-catalysed arylation of indolylzinc halides
Indolylzinc halides are prepared by two methods: transmetallation of indolyllithiums with zinc chloride and oxidative addition of active zinc to iodoindoles. The palladium-catalysed reaction of the indolylzinc halides provides a practical method for synthesizing arylindoles.